

# 開發新穎的AhR 拮抗劑針對樹突細胞 進行腫瘤免疫治療

## 主要領域 癌症治療

### 產品/技術簡介

- 能傳遞到樹狀細胞的抗AhR微質體/微質體上具有與樹狀細胞結合之胜肽或單鍵抗體, 微質體內帶有抑制AhR的小分子藥物或mRNA

### 應用


- 藉由靜脈注射藥物而活化樹狀細胞抗原呈現及細胞激素的表達, 進而活化免疫系統(CD8<sup>+</sup> T 細胞及自然殺手細胞)以攻擊癌細胞

### 優勢

- 尚未有針對樹狀細胞的免疫促進藥物

### 專利現況

- 無



# Development of Novel AhR Antagonists for Cancer Immunotherapy via Dendritic Cell Targeting

Research Area Cancer Treatment

## Technical statement

- $\alpha$ -CD11c-conjugated liposomal AhR inhibitor/The anti-CD11c peptide or ScFv is conjugated to the outside surface of liposome. Moreover, liposomes contain AhR antagonist or inhibition mRNA.

## Applications


- The drugs activate the antigen presentation and cytokine expression of dendritic cell, thereby activating the immune system ( $CD8^+$  T and NK cells) to attack cancer cells

## Advantages

- There are no immune-boosting drugs targeting dendritic cells

## Patent status

- None



計畫主持人 Project PI

李永凌副研究員



計畫成員 Member



葉承昀



Mridula



蘇聖涵



- **Website:** <https://www.ibms.sinica.edu.tw/yungling-lee/>
- **Contact person:** Yungling L. Lee
- **TEL:** +886-2-27899132
- **Email:** leolee@ibms.sinica.edu.tw